Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman

Aardvark faces severe regulatory setbacks and investor losses, with no recovery in sight.

What the company is saying

Aardvark Therapeutics has positioned ARD-101 as a 'first-in-class' treatment for hyperphagia in Prader-Willi Syndrome (PWS), emphasizing its supposed innovation and unique value proposition. The company has repeatedly assured investors that ARD-101 possesses 'a very tolerable safety profile,' aiming to instill confidence in the drug’s risk-benefit balance. In its communications, Aardvark highlights its alignment with the FDA, noting that it began dosing HERO trial patients aged 13 and older, then expanded to those 10 and older, and intended to include children as young as 4. The language used is assertive, focusing on regulatory collaboration and the breadth of the patient population targeted, which is meant to signal both scientific rigor and market potential. However, the company buries the most critical information: the trial was paused due to 'reversible cardiac observations,' a serious safety risk, and the FDA has since placed a clinical hold on all studies under the IND. There is a conspicuous absence of positive clinical results, future trial plans, or any financial guidance, leaving investors with little to anchor their expectations. The tone is defensive and damage-controlling, with management attempting to reassure stakeholders while providing minimal substantive detail about the path forward. The only notable individual mentioned is Reed Kathrein, a partner at Hagens Berman leading a legal investigation, whose involvement signals escalating legal scrutiny rather than institutional support. This narrative fits a crisis communications strategy, seeking to minimize reputational damage and legal exposure rather than to promote growth or opportunity.

What the data suggests

The disclosed numbers paint a stark picture of rapid and severe value destruction for Aardvark shareholders. On March 2, 2026, the share price collapsed by $7.02, a 56% drop, immediately following the announcement of the HERO trial’s halt. This was compounded by a further $2.16 (32%) decline on May 15, 2026, after the FDA imposed a clinical hold on the PWS asset. By May 15, 2026, the cumulative loss from the February 27, 2026 closing price was $7.92, representing a 63% erosion of shareholder value in less than three months. These declines are directly tied to negative clinical and regulatory events, with no evidence of stabilization or recovery in the share price. The company’s prior assurances about ARD-101’s safety are directly contradicted by its own admission of 'reversible cardiac observations' as the reason for pausing the trial. There is no disclosure of operational, revenue, or cash flow data, nor any detailed clinical results or adverse event rates, making it impossible to assess the company’s underlying financial health or the true risk profile of ARD-101. The only concrete data provided are the share price movements, which are both transparent and damning. An independent analyst, relying solely on these numbers, would conclude that the company is in acute distress, with its lead asset effectively frozen and investor confidence shattered. The lack of broader financial or clinical disclosures further undermines any residual credibility.

Analysis

The announcement is focused on negative realised events: a major share price decline, the pausing of a key clinical trial, and an FDA clinical hold. The language is factual and does not attempt to inflate the company's prospects; instead, it highlights regulatory setbacks and ongoing legal investigation. Only one minor forward-looking claim is present ('intended to dose patients as young as 4 years old'), but this is rendered moot by the clinical hold and trial pause. There is no evidence of exaggerated or promotional language, nor are there claims of future benefits or large capital outlays. The gap between narrative and evidence is minimal, as the announcement is grounded in adverse, realised developments. No hype is present.

Risk flags

• ●Regulatory risk is acute: the FDA has imposed a clinical hold on all ongoing studies of ARD-101, halting the company’s lead program and freezing its development pipeline. This action signals serious safety concerns and regulatory uncertainty, which can take years to resolve, if at all.
• ●Operational risk is high: the company’s only disclosed asset of significance, ARD-101, is now paused due to 'reversible cardiac observations.' This not only jeopardizes the asset’s future but also raises questions about the company’s clinical oversight and trial management.
• ●Disclosure risk is material: Aardvark previously assured investors of a 'very tolerable safety profile,' yet subsequently admitted to serious cardiac safety issues. This contradiction suggests either poor internal controls or a willingness to downplay adverse data, both of which are red flags for investors.
• ●Financial risk is severe: the share price has collapsed by 63% in less than three months, with no evidence of stabilization or recovery. The absence of any operational, revenue, or cash flow data further clouds the company’s ability to survive prolonged regulatory delays.
• ●Legal risk is escalating: the involvement of Hagens Berman and a named partner leading an investigation into the company’s disclosures signals potential securities law violations. Legal proceedings can result in costly settlements, reputational damage, and further erosion of shareholder value.
• ●Timeline/execution risk is extreme: with all clinical activity halted and no timeline for resolution, any potential upside is years away and highly speculative. Investors face the risk of indefinite delays or outright program termination.
• ●Pattern-based risk is evident: the company’s communications emphasize positive regulatory alignment and safety, only to be followed by admissions of serious safety events and regulatory intervention. This pattern undermines management credibility and increases the risk of further negative surprises.
• ●Forward-looking risk is present: the only forward-looking claim—dosing younger patients—is now unachievable under current regulatory constraints, highlighting the disconnect between management’s stated intentions and operational reality.

Bottom line

For investors, this announcement signals a company in crisis, with its lead drug program halted by regulators and its share price in freefall. The narrative of a 'first-in-class' asset with a 'very tolerable safety profile' has been decisively undermined by the company’s own admission of serious cardiac safety risks and the FDA’s subsequent clinical hold. The involvement of a prominent legal firm investigating the propriety of Aardvark’s disclosures adds another layer of risk, suggesting that management’s communications may not have been fully transparent or accurate. There are no positive clinical results, no forward-looking trial plans, and no financial guidance—only realized losses and escalating uncertainty. To change this assessment, the company would need to disclose concrete regulatory progress (such as the FDA lifting the clinical hold), detailed safety and efficacy data, and a credible plan for resuming development. Key metrics to watch in the next reporting period include any updates on the status of the clinical hold, new safety data, and evidence of financial runway or strategic alternatives. At present, this information is not actionable for a positive investment thesis; it is a clear warning signal to avoid or exit the stock, or at best, to monitor for signs of regulatory resolution before reconsidering. The single most important takeaway is that Aardvark’s investment case is broken until and unless it can resolve its regulatory and safety issues—anything else is speculation.

Announcement summary

(NASDAQ:AARD) Aardvark Therapeutics shares fell $2.16 (-32%) on May 15, 2026, after the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset. On March 2, 2026, the share price had previously dropped $7.02 (-56%) following the company's announcement that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating ARD-101 for hyperphagia in PWS patients. By May 15, 2026, the selloff erased $7.92 (63%) from the stock's February 27, 2026 closing price. The FDA's clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial and the Phase 3 open label extension (OLE) trial. Aardvark had previously emphasized ARD-101 as a "first-in-class" drug and assured investors of "a very tolerable safety profile." The company stated that its decision to pause the HERO trial was based on a serious safety risk, specifically "reversible cardiac observations." Hagens Berman's investigation continues to focus on the propriety of Aardvark's disclosures about ARD-101 safety and efficacy data, as well as communications with the FDA.

Disagree with this article?